SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

POMBILITI

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval September 28, 2023).
Why 4/10
Pombiliti is already FDA-approved and commercializing with no pending regulatory decision or pivotal readout in the next 12 months. It is one of several products in BioMarin's diversified rare-disease portfolio (alongside Voxzogo and Galafold), so its commercial ramp is a gradual growth story rather than a binary catalyst.
Actionable Insight NEUTRAL

Pombiliti is already approved and commercializing, so the next catalysts are commercial execution metrics in BioMarin's quarterly earnings reports and any potential label expansion. Watch for Q3 2026 Pombiliti+Opfolda revenue contribution when BioMarin reports earnings on November 2, 2026 (today), and monitor Sanofi's Nexviazyme competitive moves including its potential infantile-onset Pompe label expansion.

Price Chart

Loading chart...

Executive Summary

Pombiliti (cipaglucosidase alfa) is an FDA-approved enzyme replacement therapy for late-onset Pompe disease, used in combination with Opfolda (miglustat). Originally developed by Amicus Therapeutics, it was acquired by BioMarin Pharmaceutical (BMRN) in a $4.8 billion deal that closed in April 2026. The drug generated $112.5 million in 2025 sales (60% YoY growth) and is now part of BioMarin's commercial portfolio alongside Voxzogo and Galafold. Five-year Phase 3 extension data presented in October 2026 showed durable efficacy. Pombiliti faces competition from Sanofi's Nexviazyme, which has a broader label covering patients aged 1 year and older.

How It Works

Pombiliti is an enzyme replacement therapy that replaces the missing or deficient acid alpha-glucosidase (GAA) enzyme in patients with Pompe disease. It is administered intravenously and must be taken together with Opfolda (miglustat), an oral enzyme stabilizer that prevents the breakdown of the infused enzyme in the bloodstream, allowing more of it to reach the target tissues.

Trial Status

Pombiliti was FDA-approved on September 28, 2023 based on the pivotal Phase 3 PROPEL trial. Five-year open-label extension data from PROPEL were presented at the World Muscle Society congress in October 2026, showing durable efficacy and no new safety signals in 62 enzyme-experienced adult patients with late-onset Pompe disease.

The Two-Sided Case

▲ Bull Case5
Pombiliti+Opfolda generated $112.5M in 2025 sales, growing 60% year-over-year, indicating strong commercial uptake
BioMarin's global commercial infrastructure can expand Pombiliti access to new markets, as stated in the Amicus acquisition rationale
Five-year Phase 3 extension data presented October 2026 showed durable efficacy with no new safety signals, supporting long-term use
Sanofi experienced shortages of its Pompe disease drugs in August 2026, potentially creating market share opportunity for Pombiliti
Analyst consensus on BMRN is bullish (27 analysts, mean price target $91.56 vs ~$58 current, implying ~57% upside)
▼ Bear Case5
Sanofi's Nexviazyme has a broader label covering patients aged 1 year and older, versus Pombiliti's narrower indication for adults >=40kg not improving on current ERT
Sanofi reported positive Phase 3 data for Nexviazyme in infantile-onset Pompe in June 2026 and plans to seek label expansion
Pombiliti is a small part of BioMarin's overall revenue; BioMarin cut full-year 2026 EPS guidance on other pipeline charges, signaling broader company challenges
Elevated short-sale volume (z-score 1.63 vs own history) and several large institutional exits/trims in Q2 2026 suggest bearish positioning on BMRN
The drug carries a boxed warning for severe hypersensitivity reactions, infusion-associated reactions, and risk of acute cardiorespiratory failure

Upcoming Catalysts

  • Quarterly revenue and commercial execution updates in BioMarin earnings reports
  • Potential label expansion to broader Pompe patient populations
  • Sanofi Nexviazyme competitive developments including infantile-onset Pompe label expansion

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 drugs.com3 fda.gov4 biomarin.com5 biomarin.com6 biomarin.com7 biospace.com8 sanofi.com9 statnews.com10 prnewswire.com11 accessdata.fda.gov12 investors.biomarin.com